A Phase 2/3 interventional study of Tiespectus and Aflibercept in Macular Degeneration, Age-Related Macular Degeneration and Choroidal Neovascularization, sponsored by EyeBiotech Ltd.. Recruiting at 71 sites in 9 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by EyeBiotech Ltd. (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Wet Macular Degeneration with a site in United States — 7 open to participants now, 14 under way, 7 of them phase 3. Wet Macular Degeneration · United States.
Among the 49 studies in Wet Macular Degeneration with a site in United States, this one is the 2nd largest by planned enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 2/3, reaches primary completion later than 11 of the 13 other live ones, and was the 49th registered.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
Browse Wet Macular Degeneration studies →7 of the 49 studies in Wet Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
EyeBiotech Ltd. · Sites in United States, Argentina, Australia and 9 more countries
Ages 50+
4D Molecular Therapeutics · Sites in United States, Argentina, Australia and 14 more countries
Ages 50+
4D Molecular Therapeutics · Sites in United States, Puerto Rico
Ages 50+
University of Iowa · Sites in United States
Ages 50–99
MD Stem Cells · Sites in United States, Austria, United Arab Emirates
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 22 · Phase 3 19 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 960 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Median enrollment 91 across the 45 interventional studies, 22 across the 4 observational. Of the 33 that completed or were terminated, 19 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under EyeBiotech Ltd., one of the names counted as Merck & Co., Inc. Under that name alone:
EyeBiotech Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Merck & Co., Inc has 2 studies filed under Wet Macular Degeneration — fewer than ten, so there is no comparison to draw.
6 of the studies in Wet Macular Degeneration with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT04504123University of IowaMMP-9 Inhibition for Recalcitrant Wet AMD | 2026-12-31 |
| NCT051972704D Molecular Therapeutics4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 49 studies in Wet Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).
Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.
The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
This study's planned enrollment of 960 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Browse Wet Macular Degeneration studies →EyeBiotech Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
First submitted after EyeBiotech Ltd. became part of Merck & Co., Inc.
Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The main inclusion criteria include but are not limited to the following:
The main exclusion criteria include but are not limited to the following
Participants receive 3 initial administrations of tiespectus low dose every 4 weeks (Q4W), then continue to receive tiespectus low dose every 8weeks (Q8W) until week 48. After week48, participants will be treated at intervals determined based on individualized response to treatment, up to week 92.
Drug: Tiespectus
Participants receive 3 initial administrations of tiespectus high dose Q4W, then continue to receive tiespectus high dose Q8W until week48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 92
Drug: Tiespectus
Participants receive 3 initial administrations of aflibercept, then continue to receive aflibercept Q8W until week 92
Drug: Aflibercept
Administered by intravitreal (IVT) injection
Also known as: EYE201, MK-8748
Administered by intravitreal (IVT) injection
Also known as: Eylea®
Mean Change in Best-Corrected Visual Acuity (BCVA) [Early Treatment of Diabetic Retinopathy Study (ETDRS Letters)] From Baseline to Year 1
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to Year 1 will be assessed.
Time frame: Baseline and Year 1
Mean Change in BCVA (ETDRS Letters) From Baseline (Day 1) Over Time to Year 1
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The mean change in BCVA from baseline over time to year 1 will be assessed.
Time frame: Up to Year 1
Proportion of Participants Who Gain ≥5 ETDRS Letters at Year 1
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.
Time frame: Year 1
Proportion of Participants Who Gain ≥10 ETDRS Letters at Year 1
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.
Time frame: Year 1
Proportion of Participants Who Gain ≥15 ETDRS Letters at Year 1
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.
Time frame: Year 1
Proportion of Participants Who Lose ≥5 ETDRS Letters at Year 1
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.
Time frame: Year 1
Proportion of Participants Who Lose ≥10 ETDRS Letters at Year 1
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.
Time frame: Year 1
Proportion of Participants Who Lose ≥15 ETDRS Letters at Year 1
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.
Time frame: Year 1
Mean Change in Spectral Domain Optical Coherence Tomography (SD-OCT) Central Subfield Thickness (CST) From Baseline (Day 1) To Year 1
CST will be measured in microns using SD-OCT. Mean change in CST from baseline to Year 1 will be assessed.
Time frame: Baseline and Year 1
Number of Participants who Experience One or More Systemic Adverse Events (AEs)
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal clinical laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to approximately 96 weeks
Number of Participants who Experience One or More Ocular AEs
An ocular adverse event (OAE) is defined as any untoward medical occurrence involving the eye or ocular adnexa (including eyelids, conjunctiva, lacrimal apparatus, extraocular muscles, and orbit) that: Occurs or worsens after the first administration of the investigational product (IP) or a study-related ocular procedure, and does not necessarily have a causal relationship with the IP or procedure. OAEs include, but are not limited to, changes in: Symptoms (e.g., ocular pain, photophobia, floaters, blurred vision), Visual function (e.g., best-corrected visual acuity \[BCVA\], visual field). Intraocular pressure (IOP), Anterior segment findings (e.g., conjunctival hyperemia, keratitis, anterior chamber inflammation), Posterior segment findings (e.g., vitreous inflammation, retinal hemorrhages, retinal tears or detachment, macular edema), or ocular adnexa (e.g., eyelid edema, ptosis).
Time frame: Up to approximately 96 weeks
Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EYE201